Allogeneic hematopoietic stem cell transplantation allows long-term complete remission and curability in high-risk Waldenstrom's macroglobulinemia. Results of a retrospective analysis of the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire

Garnier, Alice; Robin, Marie; Larosa, Fabrice; Gouill, Steven Le; Coiteux, Valérie; Tabrizi, Reza; Bulabois, Claude‐Eric; Cacheux, Victoria; Kuentz, Mathieu; Dreyfus, Brigitte; Dreger, Peter; Rio, Bernard; Moles-Moreau, Marie-Pierre; Bilger, Karin; Bay, Jacques‐Olivier; Leblond, Véronique; Blaise, Didier; Tournilhac, Olivier; Dhédin, Nathalie

doi:10.3324/haematol.2009.017814

Cited by 25 publications

(14 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Newer therapies, including thalidomide and bortezomib have shown encouraging results; however, they were introduced during the last calendar period of this study and may have only a marginal effect on survival in this study [25][26][27][28][29]. Studies evaluating the effect of autologous stem cell transplantation in LPL/WM have been promising with low toxicities and high response rates [5,[30][31][32][33][34]. However, randomized clinical trials are lacking.…”

Section: Discussionmentioning

confidence: 99%

Patterns of survival in lymphoplasmacytic lymphoma/waldenström macroglobulinemia: A population‐based study of 1,555 patients diagnosed in Sweden from 1980 to 2005

et al. 2012

View full text Add to dashboard Cite

1980-1985, 1986-1990, 1991-1995, 1996-2000, and 2001-2005, respectively. Improvement in 1-and 5-year relative survival was found in all age groups and for LPL and WM separately. Patients with WM had lower excess mortality compared to LPL (EMRR 5 0.38; 95% CI 0.30-0.48). Older age at diagnosis was associated with a poorer survival (P < 0.001). Taken together, we found a significant improvement in survival in LPL/WM over time. Despite this progress, new effective agents with a more favourable toxicity profile are needed to further improve survival in LPL/ WM, especially in the elderly. Am. J. Hematol. 88:60-65, 2013. V

show abstract

Section: Discussionmentioning

confidence: 99%

Patterns of survival in lymphoplasmacytic lymphoma/waldenström macroglobulinemia: A population‐based study of 1,555 patients diagnosed in Sweden from 1980 to 2005

et al. 2012

View full text Add to dashboard Cite

show abstract

“…[12][13][14][15][16] However, the nonrelapse mortality within the first 2 years amounts to 15% to 25%, 6,[12][13][14]17 and approximately half the surviving patients develop chronic graft-versus-host disease (GVHD), which contributes to debilitating morbidity and nonrelapse mortality. 18 The efficacy of RIC-SCT has been attributed to a graft-versus-leukemia (GVL) effect.…”

Section: Introductionmentioning

confidence: 99%

Outcomes of Patients With Chronic Lymphocytic Leukemia and Richter's Transformation After Transplantation Failure

Rozovski

Benjamini

Jain

et al. 2015

JCO

View full text Add to dashboard Cite

Purpose Allogeneic stem-cell transplantation (SCT) induces long-term remission in a fraction of patients with high-risk chronic lymphocytic leukemia (CLL) or Richter's transformation (RT). Our purpose was to determine the outcomes of patients whose disease progressed after allogeneic SCT. Patients and Methods We retrospectively analyzed the outcomes of 72 patients (52 with CLL and 20 with RT) who underwent allogeneic SCT between 1998 and 2011 and had documented progression after transplantation. Twenty-two (31%) never had a response, and 50 (69%) had a response but experienced relapse after a median of 7 months (range, 2 to 85 months). Forty-eight patients who were receiving or were candidates to receive post-SCT cell-based therapies were not included in this analysis. Results The median age at time of transplantation was 58 years (range, 30 to 72 years). Sixty-two patients (86%) received more than two treatment regimens and 37 (51%) received more than three treatment regimens before SCT. Sixty-six patients (92%) had active disease at the time of transplantation. The 2- and 5-year survival rates were 67% and 38% (patients with CLL) and 36% and 0% (patients with RT). The patients who developed acute or chronic graft-versus-host disease had a longer overall survival (OS; P = .05). In a multivariable analysis, RT or low hemoglobin at the time of SCT predicted shorter OS. Chronic graft-versus-host disease and an initial response to SCT predicted longer OS. Conclusion Patients with CLL in whom allogeneic SCT fails may have a response to and benefit from salvage therapies, and their prognosis is relatively good.

show abstract

“…11 Further analyses should 786 haematologica | 2011; 96 (5) Letters to the Editor assess the interactions between the prognostic factors observed before salvage therapy and response; they might be particularly useful for identifying high-risk patients who may require intensive therapy, especially allogeneic stem cell transplantation, 12 despite the achievement of good response after salvage therapy.…”

mentioning

confidence: 99%

Prognostic value of the International Scoring System and response in patients with advanced Waldenstrom macroglobulinemia

Hivert¹,

Tamburini²,

Vekhoff³

et al. 2011

Haematologica

Self Cite

View full text Add to dashboard Cite

In our series, none of the 7 cases with NPM1 deletions showed at karyotypic examination a deletion that included the NPM1 gene locus at 5q35. However, it should be noted that the inaccuracy of the deleted region assignment by chromosome banding has been reported for 5q deletions in both MDS and AML. 11Our findings suggest that NPM1 haploinsufficiency may have a role in myeloid malignancies associated with large 5q-deletions contributing to MDS development likely through genetic instability. This would be in line with the finding that NPM1 is haploinsufficient in the control of centrosome duplication in the mouse model, as well as with evidence that NPM1 hypomorphic mouse embryonic fibroblasts reveal high levels of tetraploidy and aneuploidy.4 Alternatively, NPM1 deletions may represent secondary events linked to the progression of the disease in MDS.Given the low number of cases and heterogeneity of treatments, we were unable to determine here the clinical significance of NPM1 deletion in MDS with 5q-. Hence a larger series of cases including homogeneously treated patients is needed to investigate the prognostic impact of these abnormalities. 5q-and complex karyotype. Haematologica 2011; 96(05):784-785

show abstract

Allogeneic hematopoietic stem cell transplantation allows long-term complete remission and curability in high-risk Waldenstrom's macroglobulinemia. Results of a retrospective analysis of the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire

Cited by 25 publications

References 16 publications

Patterns of survival in lymphoplasmacytic lymphoma/waldenström macroglobulinemia: A population‐based study of 1,555 patients diagnosed in Sweden from 1980 to 2005

Patterns of survival in lymphoplasmacytic lymphoma/waldenström macroglobulinemia: A population‐based study of 1,555 patients diagnosed in Sweden from 1980 to 2005

Outcomes of Patients With Chronic Lymphocytic Leukemia and Richter's Transformation After Transplantation Failure

Prognostic value of the International Scoring System and response in patients with advanced Waldenstrom macroglobulinemia

Contact Info

Product

Resources

About